Close Menu

NEW YORK (360Dx) – RPRD Diagnostics today announced it and Orient Bio have inked a memorandum of understanding that will expand the availability of RPRD's pharmacogenomic testing services to South Korea.

Additionally, Orient Bio will diversify its business to include new areas, including precision medicine and clinical PGx, said RPRD, which stands for Right Patient Right Drug.

Financial and other terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.

NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.

Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.